Fangda assists Brattea in completing its high-value series-D financing_News_About

Fangda assists Brattea in completing its high-value series-D financing

2024 / 04 / 24

Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.

Previous：Fangda represents Mindray in its strategic acquisition of the controlling shareholding right of APT, a listed company on the STAR Market Board

Next：Fangda assisted Voneseals in completing a material asset restructuring transaction through equity acquisition of Shanghai Garnor

2026 / 02 / 06

Fangda Advises Muyuan on Its Successful Main Board Listing on HKEX and H-Share Offering

2026 / 02 / 03

Fangda Advises XtalPi on HKD 2.866 billion Convertible Bond Issuance

2026 / 02 / 02

Fangda Advises Eastroc Beverage on Its Strategic Partnership with Salim Group to Enter the Indonesian Market

2026 / 01 / 29

Fangda Advises Leading Clean Energy Key Materials Company Zhenshi on Its Successful Listing on the SSE Main Board

2026 / 01 / 21

Fangda Advises VeriSilicon on Acquiring Controlling Stake in Pixelworks Semiconductor